FDA IND approval of new oncolytic virotherapy CHECKvacc
Filed with ASX · · 5 pages · English
Earlier from Imugene
- Investor Presentation
- Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
- Appendix 4C - quarterly
- Imugene announces clinical milestone for HER-Vaxx
- Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
Later from Imugene
- Appendix 4C - Quarterly Report
- Imugene completes $90 M placement and launches $5 M SPP
- Prospectus for SPP and Placement Options Offer
- Research partnership with Celularity for solid tumors
- Response to ASX Query
Follow Imugene into a list and get an email when it puts out news.
Follow Imugene